Company Overview
Boehringer Ingelheim is a global leader in the pharmaceutical industry, known for its extensive research and development in the field of biopharmaceuticals. The company, with its headquarters in Ingelheim, Germany, has a strong presence in over 150 countries and employs more than 50,000 people worldwide. One of its key divisions is Boehringer Ingelheim Corporate Research (BI-CRO), which plays a pivotal role in driving innovation and advancing the company’s drug discovery and development processes.
Research Focus and Expertise
BI-CRO is dedicated to exploring new frontiers in medicine through cutting-edge research. The division’s expertise spans across various therapeutic areas, including respiratory, cardiovascular, metabolic, and oncology. Here are some of the key areas where BI-CRO excels:
| Therapeutic Area | Focus |
|---|---|
| Respiratory | Developing new treatments for asthma, COPD, and other respiratory diseases |
| Cardiovascular | Researching novel therapies for heart failure, hypertension, and other cardiovascular conditions |
| Metabolic | Investigating treatments for diabetes, obesity, and other metabolic disorders |
| Oncology | Developing targeted therapies for various types of cancer |
Drug Discovery and Development
BI-CRO is at the forefront of drug discovery and development, utilizing a combination of innovative technologies and a collaborative approach. The division’s research pipeline includes several promising drug candidates that are currently in various stages of clinical development. Here’s a glimpse into some of the key projects:
- BI 672266: A novel, oral, once-daily, non-steroidal, selective, and potent inhibitor of interleukin-17A (IL-17A) for the treatment of moderate to severe plaque psoriasis.
- BI 672267: A first-in-class, oral, selective, and potent inhibitor of interleukin-23 (IL-23) for the treatment of moderate to severe plaque psoriasis.
- BI 672268: A novel, oral, once-daily, non-steroidal, selective, and potent inhibitor of interleukin-17A (IL-17A) for the treatment of moderate to severe plaque psoriasis.
Collaborations and Partnerships
BI-CRO recognizes the importance of collaboration in driving innovation. The division has established numerous partnerships with academic institutions, biotech companies, and other pharmaceutical organizations. These collaborations aim to accelerate the development of new therapies and share knowledge and resources. Some notable partnerships include:
- Harvard University: Collaborating on the development of novel cancer therapies.
- Amgen: Partnering to develop new treatments for cardiovascular diseases.
- Regeneron Pharmaceuticals: Collaborating on the development of a new class of treatments for respiratory diseases.
Investment in Technology and Infrastructure
BI-CRO is committed to investing in state-of-the-art technology and infrastructure to support its research and development efforts. The division has a robust pipeline of projects, and its investment in technology ensures that it remains at the forefront of drug discovery and development. Some of the key technologies and infrastructure investments include:
- High-throughput screening: Utilizing advanced screening techniques to identify potential drug candidates.
- Computational biology: Leveraging computational tools to analyze complex biological data and identify new targets.
- Genomics and proteomics: Investing in next-generation sequencing and mass spectrometry to study the genetic and protein profiles of diseases.
Impact on Global Health
BI-CRO’s research and development efforts have a significant impact on global health. The division’s commitment to finding new and effective treatments for various diseases has the potential to improve the lives of millions of people worldwide. Some of the key contributions include:
- Develop
